SGX301

FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
Yahoo
Wed, 01/7/15 - 08:58 am
FDA
Soligenix
fast track
SGX301
cutaneous T-cell lymphoma